MedTrace Logo

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

NCT03426033 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-04-05

No results posted yet for this study

Summary

This is a single center, open label, single sequence, two-treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of a single dose of warfarin.

Conditions

Interventions

DRUG

ISIS 681257

Xmg dose administered as a subcutaneous injection

DRUG

Warfarin

25mg tablet administered orally

Sponsors & Collaborators

  • Akcea Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2018-02-25
Completion
2018-02-25

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426033 on ClinicalTrials.gov